Zentalis Pharmaceuticals is a biopharmaceutical company that focuses on discovering and developing small molecule cancer therapies. Their lead product candidate, ZN-c3, is in Phase 2 clinical trials for multiple uses, including advanced solid tumors. Zentalis also has multiple licensing agreements and collaborations with several well-known pharmaceutical companies.